







CLAIM AMENDMENTS

(underlines indicate insertions; strike-throughs indicate deletions)









1. (Amended) A compound of formula:



wherein R' is selected from the group consisting of
 $\text{H}_2\text{NH}_2\text{C}-$,



R'' is selected from the group consisting of



2. (Canceled)

3. (Canceled)

4. (Canceled)

5. (Canceled)

6. (Canceled)


7. (Canceled)

8. (Canceled)


9. (Canceled)

10. (Previously amended) A composition comprising at least one compound of claim 1 and a carrier.

11. (Amended) A method of treating a mammal in need of an antagonist of a δ -opioid receptor, which method comprises administering at least one compound of formula:




wherein (i) ~~R' is~~ $\text{H}_2\text{N}=\text{---}$ ~~and R'' is~~



In re Appln. of Lazarus et al.
Application No. 09/814,558


(ii) R' is $\text{H}_2\text{N}-$ and

R'' is




(iii) R' is $\text{H}_3\text{C}-$ and


R'' is



(iv) R' is




R'' is




(v) R' is $\text{H}_2\text{N}-$ and

R'' is



or (vi) (ii) R' is $\text{H}_2\text{N}-$ and

R'' is




in an amount that antagonizes a δ -opioid receptor in said mammal.

12. (Canceled)

13. (Canceled)


14. (Canceled)

15. (Original) A method of inhibiting the binding of an opioid receptor-binding compound with a P glycoprotein in a mammal, which method comprises administering at least one compound of formula:



wherein (i) R' is $\text{H}_2\text{N}-$ and


R'' is




(ii) R' is

$\text{H}_2\text{N}-$ and


R'' is



(iii) R' is




R'' is




(iv) R' is $\text{H}_2\text{N}-$ and


R" is



(v) R' is




R" is



(vi) R' is $\text{H}_2\text{N---}$ and

R" is




in an amount effect to inhibit the binding of an opioid receptor-binding compound with a P glycoprotein in a mammal.


16. (Original) The method of claim 15, wherein said P glycoprotein is P-gp1 (hMDR-1).

17. (Original) The method of claim 15, wherein said compound of formula:


In re Appln. of Lazarus et al.
Application No. 09/814,558




is the compound wherein R' is




R'' is




18. (Original) The method of claim 16, wherein said compound of formula:




is the compound wherein R' is






R" is






19. (Amended) A compound of formula:










wherein R' is selected from the group consisting of






R" is selected from the group consisting of





20. (Previously added) A composition comprising at least one compound of claim 19 and a carrier.


21. (New) A compound of formula:



wherein


(i) R' is $\text{H}_2\text{N---}$ and

R'' is selected from the group consisting of









or


(ii) R' is




R" is selected from the group consisting of




22. (New) The compound of claim 21, wherein R' is $\text{H}_2\text{N} \text{---}$ and R" is



23. (New) The compound of claim 21, wherein R' is



R'' is



24. (New) A composition comprising at least one compound of claim 21 and a carrier.